Tandem Diabetes Care (NASDAQ:TNDM) Announces Earnings Results

Tandem Diabetes Care (NASDAQ:TNDM) posted its earnings results on Wednesday. The medical device company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.19), Zacks reports. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%.

Tandem Diabetes Care Trading Up 0.7 %

Shares of TNDM traded up $0.25 during mid-day trading on Wednesday, reaching $33.59. The company had a trading volume of 1,848,890 shares, compared to its average volume of 998,159. Tandem Diabetes Care has a fifty-two week low of $25.78 and a fifty-two week high of $53.69. The firm has a fifty day simple moving average of $35.44 and a 200-day simple moving average of $36.64. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -17.40 and a beta of 1.32. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

Analyst Ratings Changes

TNDM has been the topic of several recent research reports. Sanford C. Bernstein assumed coverage on shares of Tandem Diabetes Care in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price objective on the stock. Morgan Stanley raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price target on the stock in a report on Monday, December 2nd. Robert W. Baird lowered their price target on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a research report on Thursday, November 7th. Canaccord Genuity Group restated a “buy” rating and set a $63.00 price objective on shares of Tandem Diabetes Care in a research report on Wednesday. Finally, Barclays upped their target price on Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $54.25.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.